Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-HDS1,2 plus Zevalin versus R-CHOP in elderly patients with diffuse large B-cell lymphoma
2006-002524-42Phase 3Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan, rituximab, cyclophosphamide, doxorubicin, vincristine and 2 more in diffuse large B-cell lymphoma (DLBCL) and lymphoma (2 arms), sponsored by Michelangelo Foundation. Primary endpoint: Disease-free survival. Started Mar 2007; status: terminated.
02
Drugs
ibritumomab tiuxetanrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)lymphoma
Beyond the preview
Go deeper on 2006-002524-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002524-42.